Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

Rheumatology

Volumn 51, Issue 3, 2012, Pages 491-498

  Lopez, Rekha ^a   Davidson, Julie E ^b   Beeby, Matthew D ^b   Egger, Peter J ^b   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Disease activity; Organ damage; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID;

ADULT; AGED; ARTICLE; BILAG SCORE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY INJURY; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL INJURY; ORGAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RETROSPECTIVE STUDY; RISK FACTOR; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PROSPECTIVE STUDIES; RESPIRATORY TRACT DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84857564258     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker368     Document Type: Article

References (41)

1. Chambers SA, Allen E, Rahman A et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009;48:673-5.
2. Urowitz MB, Gladman DD, Tom BDM et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35: 2152-8.
3. Toloza SMA, Roseman JM, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177-86.
4. Stoll T, Sutcliffe N, Mach J et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology 2004;43:1039-44.
5. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-58.
6. Bencivelli W, Vitali C, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992;10: 549-54.
7. Gladman DD, Goldsmith CH, Urowitz MB et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-11.
8. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
9. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7.
10. Nossent J, Kiss E, Rozman B et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
11. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum 1982;25:1271-7.
12. Cresswell L, Yee CS, Farewell V et al. Numerical scoring for the Classic BILAG index. Rheumatology 2009;48: 1548-52.
13. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32: 824-7.
14. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;20:187-220.
15. Jacobsen S, Petersen J, Ullman S et al. Mortality and causes of death of 513 danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999;28:75-80.
16. Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001;28:266-74.
17. Nossent JC. SLICC/ACR damage index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998;25:654-9.
18. Gordon C, Sutcliffe N, Skan J et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-9.
19. Nossent JC, Cikes N, Kiss E et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007;16:309-17.
20. Stoll T, Sutcliffe N, Klaghofer R, et al.. Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: A prospective study. Ann Rheum Dis 2000;59:832-5.
21. Bujan S, Ordi-Ros J, Paredes J et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 2003;62:859-65.
22. Bertoli AM, Alarcon GS, Calvo-Alen J et al. Systemic lupus erythematosus in a multiethnic US cohort: clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006;54:1580-7.
23. Avalos I, Rho YH, Chung CP et al. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:S5-13.
24. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:S72-9.
25. Rahman P, Gladman DD, Urowitz MB et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
26. Bastian HM, Mickail I, Straaton KV et al. Factors associated with early death in African-American and Hispanic patients with SLE. Arthritis Rheum 1997;40(Suppl. 9):S160.
27. Fortin PR, Feland D, Clarke AE et al. Activity and damage predict later flares in lupus. Arthritis Rheum 1997; 40(Suppl. 9):S207.
28. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
29. Levey AS, Lan SP, Corwin HL et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone' and short-term oral cyclophosphamide. Ann Intern Med 1992;116:114-23.
30. Rabbani MA, Habib HB, Islam M et al. Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan. Lupus 2010; 19:1573-8.
31. Adler M, Chambers S, Edwards C et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology 2006; 45:1144-7.
32. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
33. Bernatsky S, Joseph L, Boivin JF et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008;67:74-9.
34. Boumpas DT, Ustin HA III., Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
35. Ioannidis JPA, Katsifis GE, Tzioufas AG et al. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002;29: 2129-35.
36. Park MC, Park YB, Jung SY et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004;13:569-74.
37. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001;10:154-61.
38. Van Der Schouw YT, Van Der Graaf Y, Steyerberg EW et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-8.
39. Cann CE, Martin MC, Genant HK et al. Decreased spinal mineral content in amenorrheic women. J Am Med Assoc 1984;251:626-9.
40. Thamer M, Hernan MA, Zhang Y, Cotter D., Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
41. Zonana-Nacach A, Barr SG, Magder LS et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.